Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trospium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 12/20 | 0.89 |
| ▸ | CHRM2 known ✓ | P08172 | 11/20 | 0.89 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.89 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.89 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.86 |
| ▸ | HRH1 | P35367 | 3/20 | 0.86 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trospium SCHEMBL29389006 | 0.94 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL13836646 | 0.94 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL25785 | 0.94 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL111738 | 0.94 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL29629492 | 0.94 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL724191 | 0.93 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL2447242 | 0.93 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL119810 | 0.93 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL31112961 | 0.92 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL22609933 | 0.92 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401740-A1 | METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC COPD WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS | SUNOVION RESPIRATORY DEVELOPMENT INC. (US) | 2021-12-30 | — | — | US | disclosed |
| US-10940110-B2 | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations | SUNOVION RESPIRATORY DEVELOPMENT INC. (US) | 2021-03-09 | — | — | US | disclosed |
| EP-3311820-A1 | METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS | Sunovion Respiratory Development Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170202787-A1 | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED BETA 2-AGONIST OR COMBINED NEBULIZED BETA 2-AGONIST AND ANTICHOLINERGIC ADMINISTRATION | ELEVATION PHARMACEUTICALS, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170112763-A1 | METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS | SUNOVION RESPIRATORY DEVELOPMENT INC. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160374987-A1 | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED BETA 2-AGONIST OR COMBINED NEBULIZED BETA 2-AGONIST AND ANTICHOLINERGIC ADMINISTRATION | ELEVATION PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| US-20160166506-A1 | METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS | ELEVATION PHARMACEUTICALS, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20150141481-A1 | Treatment of Chronic Obstructive Pulmonary Disease with Nebulized Beta 2-Agonist or Combined Nebulized Beta 2-Agonist and Anticholinergic Administration | ELEVATION PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20140255491-A1 | Method and System For the Treatment of Chronic Obstructive Pulmonary Disease With Nebulized Anticholinergic Administrations | SUNOVION RESPIRATORY DEVELOPMENT INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140018406-A1 | Treatment of Chronic Obstructive Pulmonary Disease With Nebulized Beta 2-Agonist or Combined Nebulized Beta 2-Agonist and Anticholinergic Administration | SUNOVION RESPIRATORY DEVELOPMENT, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| EP-2440196-A1 | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED BETA 2-AGONIST OR COMBINED NEBULIZED BETA 2-AGONIST AND ANTICHOLINERGIC ADMINISTRATION | Elevation Pharmaceuticals, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010144628-A2 | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED BETA 2-AGONIST OR COMBINED NEBULIZED BETA 2-AGONIST AND ANTICHOLINERGIC ADMINISTRATION | ELEVATION PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100055045-A1 | METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS | SUNOVION RESPIRATORY DEVELOPMENT INC. | 2010-03-04 | — | — | US | disclosed |
| US-20090215734-A1 | METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS | ELEVATION PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |